Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumorsReportar como inadecuado




Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 9:17

First Online: 14 January 2009Received: 01 August 2008Accepted: 14 January 2009DOI: 10.1186-1471-2407-9-17

Cite this article as: Savola, S., Klami, A., Tripathi, A. et al. BMC Cancer 2009 9: 17. doi:10.1186-1471-2407-9-17

Abstract

BackgroundEwing sarcoma family of tumors ESFT, characterized by t11;22q24;q12, is one of the most common tumors of bone in children and young adults. In addition to EWS-FLI1 gene fusion, copy number changes are known to be significant for the underlying neoplastic development of ESFT and for patient outcome. Our genome-wide high-resolution analysis aspired to pinpoint genomic regions of highest interest and possible target genes in these areas.

MethodsArray comparative genomic hybridization CGH and expression arrays were used to screen for copy number alterations and expression changes in ESFT patient samples. A total of 31 ESFT samples were analyzed by aCGH and in 16 patients DNA and RNA level data, created by expression arrays, was integrated. Time of the follow-up of these patients was 5–192 months. Clinical outcome was statistically evaluated by Kaplan-Meier-Logrank methods and RT-PCR was applied on 42 patient samples to study the gene of the highest interest.

ResultsCopy number changes were detected in 87% of the cases. The most recurrent copy number changes were gains at 1q, 2, 8, and 12, and losses at 9p and 16q. Cumulative event free survival ESFT and overall survival OS were significantly better P < 0.05 for primary tumors with three or less copy number changes than for tumors with higher number of copy number aberrations. In three samples copy number imbalances were detected in chromosomes 11 and 22 affecting the FLI1 and EWSR1 loci, suggesting that an unbalanced t11;22 and subsequent duplication of the derivative chromosome harboring fusion gene is a common event in ESFT. Further, amplifications on chromosomes 20 and 22 seen in one patient sample suggest a novel translocation type between EWSR1 and an unidentified fusion partner at 20q. In total 20 novel ESFT associated putative oncogenes and tumor suppressor genes were found in the integration analysis of array CGH and expression data. Quantitative RT-PCR to study the expression levels of the most interesting gene, HDGF, confirmed that its expression was higher than in control samples. However, no association between HDGF expression and patient survival was observed.

ConclusionWe conclude that array CGH and integration analysis proved to be effective methods to identify chromosome regions and novel target genes involved in the tumorigenesis of ESFT.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-9-17 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Suvi Savola - Arto Klami - Abhishek Tripathi - Tarja Niini - Massimo Serra - Piero Picci - Samuel Kaski - Diana Zambelli -

Fuente: https://link.springer.com/







Documentos relacionados